Literature DB >> 33585500

MAC Project-Monitoring Anticoagulant Therapy Observational Study: Rationale and Protocol.

Giuseppe Camporese1, Enrico Bernardi2, Cristiano Bortoluzzi3, Franco Noventa4, Ngoc Vo Hong3, Elena Callegari5, Sabina Villalta5, Chiara Tonello1, Michela Nardin3, Elena Campello6, Luca Spiezia6, Paolo Simioni6.   

Abstract

Real-life studies complement data from registrative trials. Because of the delayed registration of direct oral anticoagulants in Italy, scarce real-life data on such treatments is available for the Italian population. The aim of the MAC project is to collect real-life clinical information in unselected patients given oral anticoagulants for venous thromboembolism, during a 5-year follow-up period. This is a prospective-cohort, multi-center, observational study performed in four Italian centers. The estimated samples size is 4,000 patients. The efficacy outcomes are: incidence of symptomatic recurrent venous thromboembolism and of post-thrombotic syndrome. The safety outcomes are: incidence of major bleeding, clinically relevant non-major bleeding, minor bleeding, serious adverse events, and mortality. The MAC project has the potential to improve our understanding of the epidemiology and of the therapeutic strategies adopted in Italian patients with venous thromboembolism. Clinical Trial Registration: WWW.ClinicalTrials.Gov, identifier: NCT0432939.
Copyright © 2021 Camporese, Bernardi, Bortoluzzi, Noventa, Hong, Callegari, Villalta, Tonello, Nardin, Campello, Spiezia and Simioni.

Entities:  

Keywords:  anticoagulants; deep vein thrombosis; direct oral anticoagulant; monitoring; pulmonary embolism

Year:  2021        PMID: 33585500      PMCID: PMC7876063          DOI: 10.3389/fmed.2020.584459

Source DB:  PubMed          Journal:  Front Med (Lausanne)        ISSN: 2296-858X


  20 in total

1.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

2.  A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment.

Authors:  Alexander G G Turpie; Sylvia Haas; Reinhold Kreutz; Lorenzo G Mantovani; Cassandra W Pattanayak; Gerlind Holberg; Waheed Jamal; André Schmidt; Martin van Eickels; Michael R Lassen
Journal:  Thromb Haemost       Date:  2013-10-24       Impact factor: 5.249

3.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.

Authors:  Clive Kearon; Elie A Akl; Joseph Ornelas; Allen Blaivas; David Jimenez; Henri Bounameaux; Menno Huisman; Christopher S King; Timothy A Morris; Namita Sood; Scott M Stevens; Janine R E Vintch; Philip Wells; Scott C Woller; Lisa Moores
Journal:  Chest       Date:  2016-01-07       Impact factor: 9.410

4.  Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study.

Authors:  A Cogo; A W Lensing; M M Koopman; F Piovella; S Siragusa; P S Wells; S Villalta; H R Büller; A G Turpie; P Prandoni
Journal:  BMJ       Date:  1998-01-03

5.  Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.

Authors:  Walter Ageno; Lorenzo G Mantovani; Sylvia Haas; Reinhold Kreutz; Danja Monje; Jonas Schneider; Martin van Eickels; Martin Gebel; Elizabeth Zell; Alexander G G Turpie
Journal:  Lancet Haematol       Date:  2015-12-08       Impact factor: 18.959

6.  Efficacy and safety of dabigatran in a "real-life" population at high thromboembolic and hemorrhagic risk: data from MonaldiCare registry.

Authors:  V Russo; V Bianchi; C Cavallaro; F Vecchione; S De Vivo; L Santangelo; B Sarubbi; P Calabrò; G Nigro; A D'Onofrio
Journal:  Eur Rev Med Pharmacol Sci       Date:  2015-10       Impact factor: 3.507

7.  The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation.

Authors:  Emilia Antonucci; Daniela Poli; Alberto Tosetto; Vittorio Pengo; Armando Tripodi; Nicola Magrini; Francesco Marongiu; Gualtiero Palareti
Journal:  PLoS One       Date:  2015-05-22       Impact factor: 3.240

8.  Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study.

Authors:  Min Jun; Lisa M Lix; Madeleine Durand; Matt Dahl; J Michael Paterson; Colin R Dormuth; Pierre Ernst; Shenzhen Yao; Christel Renoux; Hala Tamim; Cynthia Wu; Salaheddin M Mahmud; Brenda R Hemmelgarn
Journal:  BMJ       Date:  2017-10-17

9.  Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary.

Authors:  Hein Heidbuchel; Peter Verhamme; Marco Alings; Matthias Antz; Hans-Christoph Diener; Werner Hacke; Jonas Oldgren; Peter Sinnaeve; A John Camm; Paulus Kirchhof
Journal:  Eur Heart J       Date:  2017-07-14       Impact factor: 29.983

10.  Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study.

Authors:  Alexander T Cohen; Cihan Ay; Philippe Hainaut; Hervé Décousus; Ulrich Hoffmann; Sean Gaine; Michiel Coppens; Pedro Marques da Silva; David Jimenez Castro; Beatrice Amann-Vesti; Bernd Brüggenjürgen; Pierre Levy; Julio Lopez Bastida; Eric Vicaut; Petra Laeis; Eva-Maria Fronk; Wolfgang Zierhut; Thomas Malzer; Peter Bramlage; Giancarlo Agnelli
Journal:  Thromb J       Date:  2018-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.